Biohaven Ltd. (BHVN) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the BioHaven Pharmaceuticals Q2 2021 earnings call and webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. If anyone should require operator assistance, please press star zero on your telephone keypad. Please be advised that today's conference call may be recorded. I will now hand the conference over to Caroline Dirks from BioHaven. Thank you. Please go ahead. Thank you, and welcome to the BioHaven second quarter 2021 earnings call. Speaking on today's call are Dr. Vlad Chorich, our Chief Executive Officer, Jim Englehart, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Dr. Elise Stock, Chief Medical Officer. Earlier this morning, we issued a press release announcing the second quarter 2021 highlights. A copy of this press release can be found on our website at biohavenpharma.com and we will file our Form 10-Q later today. Before we begin, let me remind everyone that today's discussion contains forward-looking statements based on the environment as we currently see it, and includes risks and uncertainties. A list and description of risks and uncertainties associated with an investment in Biohaven can be found in the company's filings with the U.S. Securities and Exchange Commission. Please be aware that you should not place undue reliance on any forward-looking statements we make today. For this call, we will focus on non-GAAP financial measures. Detailed descriptions of these non-GAAP measures and reconciliations to the most comparable GAAP measures can be found in our SEC filings. An archive of today's call will be posted to Biohaven's website in the Investor Relations section. With that, I will turn the call over to our CEO, Dr. ...